GlassScriptPhysician profile
Jillian M Smith
NPI 1215392774
$8,898.94
in general payments reported to CMS, 2019-2025
20 companies · $4,559 in 2025
The $4,559 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $474 · 2022: $386 · 2023: $908 · 2024: $2,572 · 2025: $4,559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,814 · Travel and Lodging: $2,975 · Consulting Fee: $1,250 · Education: $1.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,813.59 |
| Travel and Lodging | $2,974.69 |
| Consulting Fee | $1,250.00 |
| Education | $1.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $6,045.15 | 2021-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Abbott Laboratories | $874.50 | 2023-2025 | Navitor, Cardiomems |
| Merck Sharp & Dohme LLC | $312.00 | 2023-2025 | Verquvo |
| Novartis Pharmaceuticals Corporation | $253.73 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $201.26 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $200.70 | 2021-2025 | Wainua, Farxiga |
| Pfizer INC. | $126.38 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $119.81 | 2025 | |
| Janssen Pharmaceuticals, INC | $108.74 | 2021-2024 | Xarelto |
| Heartflow, INC. | $90.87 | 2023-2024 | Ffrct |
| E.R. Squibb & Sons, L.L.C. | $90.14 | 2023-2025 | Camzyos |
| Cvrx, INC. | $82.82 | 2023-2025 | Barostim Neo System |
| Actelion Pharmaceuticals US, INC. | $70.53 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $69.62 | 2023-2025 | Lifevest |
| Bridgebio Pharma, INC. | $66.91 | 2025 | Attruby |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $63.50 | 2021 | |
| Esperion Therapeutics, INC. | $45.29 | 2023-2024 | Nexletol |
| Alnylam Pharmaceuticals INC. | $32.98 | 2021-2024 | Onpattro |
| Scpharmaceuticals INC. | $28.11 | 2024 | |
| Akcea Therapeutics, INC. | $15.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jillian Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.